NASDAQ: LRMR
Larimar Therapeutics Inc Stock Ownership - Who owns Larimar Therapeutics?

Insider buying vs selling

Have Larimar Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Thomas Edward HamiltonDirector2026-07-0650,000$3.34
$166.90kBuy
James E. FlynnDirector2026-02-271,084,012$5.00
$5.42MBuy
James E. FlynnDirector2026-02-27831,978$5.00
$4.16MBuy
James E. FlynnDirector2026-02-272,000,000$5.00
$10.00MBuy
Thomas Edward HamiltonDirector2026-02-27100,000$5.00
$500.00kBuy
Jeffrey W. ShermanDirector2026-02-275,000$5.00
$25.00kBuy
James E. FlynnDirector2026-02-271,084,010$5.00
$5.42MBuy
Frank E. ThomasDirector2026-02-275,000$5.00
$25.00kBuy

1 of 1

LRMR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LRMR insiders and whales buy or sell their stock.

LRMR Shareholders

What type of owners hold Larimar Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
James E. Flynn41.55%43,164,915$169.21MInsider
Peter Barrett9.89%10,276,057$40.28MInsider
Bruce Booth9.89%10,270,758$40.26MInsider
Deerfield Partners LP2.67%2,777,777$10.89MInsider
Thomas Edward Hamilton1.00%1,033,664$4.05MInsider
Avi Y. Goldberg0.39%401,376$1.57MInsider
Carole Benmaimon0.38%399,432$1.57MInsider
Kevin P. Starr0.36%370,323$1.45MInsider
Michael Celano0.21%215,785$845.88kInsider
Thomas E. Hughes0.12%125,247$490.97kInsider

1 of 3

LRMR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LRMR0.09%66.77%Net BuyingNet Buying
RZLT0.08%99.92%Net BuyingNet Selling
EDIT0.08%21.44%Net SellingNet Selling
BBOT0.07%42.54%Net SellingNet Selling
ARCT0.09%12.98%

Larimar Therapeutics Stock Ownership FAQ

Who owns Larimar Therapeutics?

Larimar Therapeutics (NASDAQ: LRMR) is owned by 0.09% institutional shareholders, 66.77% Larimar Therapeutics insiders, and 33.14% retail investors. James E. Flynn is the largest individual Larimar Therapeutics shareholder, owning 43.16M shares representing 41.55% of the company. James E. Flynn's Larimar Therapeutics shares are currently valued at $169.21M.

If you're new to stock investing, here's how to buy Larimar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.